FibroGen, Inc. announced the appointment of John Hunter to the position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience. Dr. Hunter most recently served as Chief Executive & Scientific Officer of Keyhole Therapeutics Inc. Prior to Keyhole, John spent 8 years at Compugen Limited, where he was most recently Chief Scientific Officer & US Site Head.